All the Active Ingredient Drugs
Engineered Autologous T Cell Immunotherapy product. lisocabtagene maraleucel 1.1-70 x 10^6 cells/mL. Vial 1X 4.6 ml for IV inf.
For autologous use.
Tmt. of adults with large B-cell lymphoma (LBCL), incl. diffuse large B-cell lymphoma (DLBCL) not otherwise specif. (including DLBCL arising from indolent lymphoma), high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have:
refract. dis. to first-line chemoimmunother. or relapse within 12 months of first-line chemoimmunother.;or
refract. dis. to first-line chemoimmunother. or relapse after first-line chemoimmunother. and are not eligible for hematopoetic stem cell transplant. (HSCT) due to comorbidities or age.
Tmt. of adults with relapsed or refract. diffuse large B-cell lymphoma(DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), after two or more lines of syst. ther.
Tmt. of adults with relapsed or refract. follicular lymphoma (FL) after two or more lines of syst. ther.
Tmt. of adults with relapsed or refract. mantle cell lymphoma (MCL) after at least two lines of syst. ther. incl. a Bruton's tyrosine kinase (BTK) inhib.
C/I:Hypersens. Contraindic. of the lymphodepleting chemother. must be considered.
